Sangamo Stock Plummets Post-Pfizer Deal

This is a haemophilia news story, published by Yahoo Finance, that relates primarily to Pfizer news.

haemophilia news

For more haemophilia news, you can click here:

more haemophilia news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

gene therapy partnership

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest gene therapy programmes news, gene therapy option news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

Sangamo Therapeutics

GlobalData

•

Sangamo’s stock sinks 50% as Pfizer halts haemophilia A gene therapy partnership

Summary

Nutrition label

87% Informative

Sangamo Therapeutics’ stock has plummeted by 50% in premarket trading after Pfizer ended the companies’ partnership to co-develop a gene therapy for haemophilia A.

Sangamo plans to explore options to advance the programme, including seeking a new collaboration partner.

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive

Hate speech